Sitravatinib + Nivo Adv/Met Urothelial
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
NeoAdj Chemo +/- Nivo/IDO1inh MIBC
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078) Read More
Phase: III
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II
TALAZ IN GERMLINE BRCA1/2 MUT BC
(C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER Read More
Phase: II
TALAZ IN GERMLINE BRCA1/2 MUT BC
(C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER Read More
Phase: II
Ph3 Abemaciclib HR+ HER2- (monarchE)
(I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer Read More
Phase: III
Ph3 Abemaciclib HR+ HER2- (monarchE)
(I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer Read More
Phase: III
Ph1 SY-1365 Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101 Read More
Phase: I
Ph1 SY-1365 Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101 Read More
Phase: I
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304) Read More
Phase: III
Adj Therapy Node+orHRNode-3-Inv TNBC
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) Read More
Phase: III
Ph3 Pembro HR+/HER2- BC
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More
Phase: III
Ph3 Pembro HR+/HER2- BC
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More
Phase: III
Ublituximab+TGR-1202 Cross-over
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More
Phase: II
Ublituximab+TGR-1202 Cross-over
(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More
Phase: II
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph3 R/R CLL/SLL
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305) Read More
Phase: III
Ph3 R/R CLL/SLL
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305) Read More
Phase: III
Ph3b 1L CLL debulk combo
A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788) Read More
Phase: III
Ph3b 1L CLL debulk combo
A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788) Read More
Phase: III
Ph3 HR MDS, CMML, AML
Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More
Phase: III
Ph3 HR MDS, CMML, AML
Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More
Phase: III
Ph 1/1b Immunotherapy Combo in NSCLC
(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More
Phase: I
Ph 1/1b Immunotherapy Combo in NSCLC
(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More
Phase: I
Ph2 MGCDs+Nivo NSCLC
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500) Read More
Phase: II
Ph2 MGCDs+Nivo NSCLC
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500) Read More
Phase: II
Ph1 TSR-022 Adv Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More
Phase: I
Ph1 TSR-022 Adv Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Tepotinib stage IIIB/IV NSCLC w/ METex14
A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022 Read More
Phase: II
Tepotinib stage IIIB/IV NSCLC w/ METex14
A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022 Read More
Phase: II
Ph3 neoadj Atezo NSCLC
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (GO40241) Read More
Phase: III
Ph3 neoadj Atezo NSCLC
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (GO40241) Read More
Phase: III
Ph 1b/2 copanlisib+nivo solid tumors
An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More
Phase: I/II
Ph 1b/2 copanlisib+nivo solid tumors
An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More
Phase: I/II
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002)
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002) Read More
Phase: II
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002)
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002) Read More
Phase: II
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More
Phase: III
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More
Phase: III
Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC
CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Read More
Phase: III/IV
Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC
CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Read More
Phase: III/IV
Ph3 Nivo vs Plat-Doublet chemo NSCLC
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) Read More
Phase: III
Ph3 Nivo vs Plat-Doublet chemo NSCLC
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) Read More
Phase: III
PhIV Gazyva, Adv FL
(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY) Read More
Phase: IV
PhIV Gazyva, Adv FL
(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY) Read More
Phase: IV
STAR BV in older pts w/1L cHL or PTCL
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above Read More
Phase: II
STAR BV in older pts w/1L cHL or PTCL
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above Read More
Phase: II
Ph2 R/R MCL (CITADEL-205)
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205 Read More
Phase: II
Ph2 R/R MCL (CITADEL-205)
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205 Read More
Phase: II
TGR-1202 +/- Ublituximab in NHL
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205) Read More
Phase: II
TGR-1202 +/- Ublituximab in NHL
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205) Read More
Phase: II
Ph3 R/R CLL/SLL
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305) Read More
Phase: III
Ph3 R/R CLL/SLL
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305) Read More
Phase: III
Ph1 INCB050465 B-Cell (CITADEL-112)
INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Read More
Phase: I
Ph1 INCB050465 B-Cell (CITADEL-112)
INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Read More
Phase: I
Ph1 TSR-022 Adv Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More
Phase: I
Ph1 TSR-022 Adv Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph3 HR MDS, CMML, AML
Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More
Phase: III
Ph3 HR MDS, CMML, AML
Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Read More
Phase: III
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
STAR Ph2 Itacitinib +/- Ruxo in MF
INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Read More
Phase: II
STAR Ph2 Itacitinib +/- Ruxo in MF
INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Read More
Phase: II
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph 1/2 PIM kinase Adv Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More
Phase: I
Ph1/2 INCB001158 + SC Dara vs Dara SC MM
A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206) Read More
Phase: I/II
Ph1/2 INCB001158 + SC Dara vs Dara SC MM
A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206) Read More
Phase: I/II
Ph4 Ixazomib+Lena & Dex MM (MM-6)
C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV) Read More
Phase: IV
Ph4 Ixazomib+Lena & Dex MM (MM-6)
C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV) Read More
Phase: IV
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
STAR Abirat+pred +/- abemaciclib mCRPC
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More
Phase: II
STAR Abirat+pred +/- abemaciclib mCRPC
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More
Phase: II
STAR Ph2 Rucaparib mCRPC (TRITON 2)
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 Read More
Phase: II
STAR Ph2 Rucaparib mCRPC (TRITON 2)
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052 Read More
Phase: II
STAR Rucaparib v PhysC mCRPC (TRITON3)
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More
Phase: III
STAR Rucaparib v PhysC mCRPC (TRITON3)
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More
Phase: III
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph3 Pembro RCC post nephrectomy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) Read More
Phase: III
Ph3 Pembro RCC post nephrectomy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) Read More
Phase: III
Ph1 SY-1365 Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101 Read More
Phase: I
Ph1 SY-1365 Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101 Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph1/1b MGCD516 Solid tumors
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) Read More
Phase: I
Ph 1b/2 copanlisib+nivo solid tumors
An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More
Phase: I/II
Ph 1b/2 copanlisib+nivo solid tumors
An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More
Phase: I/II
CheckMate 848: Ph2 Nivo+Ipi Solid tumors
CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More
Phase: II
CheckMate 848: Ph2 Nivo+Ipi Solid tumors
CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More
Phase: II
Sitravatinib + Nivo Adv/Met Urothelial
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
Sitravatinib + Nivo Adv/Met Urothelial
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR INCB054828 Urothelial FGF/FGFR
A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201) Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II
STAR Ph2 enfortumab (ASG-22CE)Urothelial
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More
Phase: II